Sign up to access all valuation multiples
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
2018
109
Last FY Revenue n/a
LTM EBITDA -$165M
$555M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of January 2026, MapLight Therapeutics reported last 12-month EBITDA of -$165M.
In the same period, MapLight Therapeutics achieved -$128M in LTM net income.
See MapLight Therapeutics valuation multiples based on analyst estimatesIn the most recent fiscal year, MapLight Therapeutics reported EBITDA of -$82.2M.
MapLight Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MapLight Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$165M | XXX | -$82.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$135M | XXX | -$82.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$128M | XXX | -$77.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MapLight Therapeutics has current market cap of $776M, and EV of $555M.
As of February 4, 2026, MapLight Therapeutics's stock price is $17.
See MapLight Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $555M | $776M | XXX | XXX | XXX | XXX | $-6.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialMapLight Therapeutics's trades at n/a EV/Revenue multiple, and -3.4x EV/EBITDA.
See valuation multiples for MapLight Therapeutics and 15K+ public compsAs of February 4, 2026, MapLight Therapeutics has market cap of $776M and EV of $555M.
Equity research analysts estimate MapLight Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MapLight Therapeutics has a P/E ratio of -6.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $776M | XXX | $776M | XXX | XXX | XXX |
| EV (current) | $555M | XXX | $555M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.4x | XXX | -3.4x | XXX | XXX | XXX |
| EV/EBIT | -4.1x | XXX | -4.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.0x | XXX | -6.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMapLight Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
MapLight Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MapLight Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MapLight Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MapLight Therapeutics acquired XXX companies to date.
Last acquisition by MapLight Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . MapLight Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was MapLight Therapeutics founded? | MapLight Therapeutics was founded in 2018. |
| Where is MapLight Therapeutics headquartered? | MapLight Therapeutics is headquartered in United States of America. |
| How many employees does MapLight Therapeutics have? | As of today, MapLight Therapeutics has 109 employees. |
| Who is the CEO of MapLight Therapeutics? | MapLight Therapeutics's CEO is Mr. Christopher A. Kroeger, M.D.. |
| Is MapLight Therapeutics publicy listed? | Yes, MapLight Therapeutics is a public company listed on NAS. |
| What is the stock symbol of MapLight Therapeutics? | MapLight Therapeutics trades under MPLT ticker. |
| When did MapLight Therapeutics go public? | MapLight Therapeutics went public in 2025. |
| Who are competitors of MapLight Therapeutics? | Similar companies to MapLight Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of MapLight Therapeutics? | MapLight Therapeutics's current market cap is $776M |
| Is MapLight Therapeutics profitable? | Yes, MapLight Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MapLight Therapeutics? | MapLight Therapeutics's last 12 months EBITDA is -$165M. |
| What is the current EV/EBITDA multiple of MapLight Therapeutics? | Current EBITDA multiple of MapLight Therapeutics is -3.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
